Adamas Pharmaceuticals Inc (ADMS) Shares Sold by Granite Point Capital Management L.P.

Granite Point Capital Management L.P. lessened its position in shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) by 71.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 54,822 shares of the specialty pharmaceutical company’s stock after selling 139,893 shares during the quarter. Granite Point Capital Management L.P.’s holdings in Adamas Pharmaceuticals were worth $468,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Alps Advisors Inc. grew its stake in Adamas Pharmaceuticals by 31.3% during the 4th quarter. Alps Advisors Inc. now owns 63,166 shares of the specialty pharmaceutical company’s stock valued at $539,000 after purchasing an additional 15,050 shares during the last quarter. First Mercantile Trust Co. grew its stake in Adamas Pharmaceuticals by 43.2% during the 4th quarter. First Mercantile Trust Co. now owns 5,765 shares of the specialty pharmaceutical company’s stock valued at $49,000 after purchasing an additional 1,740 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Adamas Pharmaceuticals during the 4th quarter valued at about $210,000. Rhumbline Advisers grew its stake in Adamas Pharmaceuticals by 46.9% during the 4th quarter. Rhumbline Advisers now owns 29,781 shares of the specialty pharmaceutical company’s stock valued at $254,000 after purchasing an additional 9,514 shares during the last quarter. Finally, Fosun International Ltd grew its stake in Adamas Pharmaceuticals by 228.3% during the 4th quarter. Fosun International Ltd now owns 196,959 shares of the specialty pharmaceutical company’s stock valued at $1,664,000 after purchasing an additional 136,959 shares during the last quarter. Institutional investors and hedge funds own 88.26% of the company’s stock.

Shares of ADMS opened at $9.00 on Monday. Adamas Pharmaceuticals Inc has a 52 week low of $7.42 and a 52 week high of $36.63. The company has a current ratio of 8.95, a quick ratio of 8.74 and a debt-to-equity ratio of 1.01. The stock has a market capitalization of $245.24 million, a PE ratio of -2.27 and a beta of 1.41.

Several analysts have weighed in on ADMS shares. Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, January 24th. ValuEngine downgraded Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, February 4th. Leerink Swann reiterated an “outperform” rating on shares of Adamas Pharmaceuticals in a research note on Friday, October 19th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Adamas Pharmaceuticals in a research note on Monday, November 5th. Finally, Mizuho reiterated a “hold” rating and set a $11.00 price target on shares of Adamas Pharmaceuticals in a research note on Friday, January 11th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $31.25.

TRADEMARK VIOLATION WARNING: “Adamas Pharmaceuticals Inc (ADMS) Shares Sold by Granite Point Capital Management L.P.” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://transcriptdaily.com/2019/02/11/adamas-pharmaceuticals-inc-adms-shares-sold-by-granite-point-capital-management-l-p.html.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

Featured Article: What is a Derivative?

Want to see what other hedge funds are holding ADMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adamas Pharmaceuticals Inc (NASDAQ:ADMS).

Institutional Ownership by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply